Secretome Therapeutics
Secretome Therapeutics develops products to combat diseases caused by inflammation and mitochondrial dysfunction.
Founded
2018Secretome Therapeutics develops products to combat diseases caused by inflammation and mitochondrial dysfunction.
Secretome Therapeutics, founded with a mission to combat diseases driven by inflammation and mitochondrial dysfunction, focuses on developing innovative secretome products. The company is pioneering cell therapy using neonatal cardiac progenitor cells to address these health challenges. Their market focus includes developing therapeutic solutions for conditions where traditional treatments may fall short, leveraging cutting-edge biotechnology to improve patient outcomes.
Notable affiliated individuals and investors include leading experts in biotechnology and healthcare investment firms committed to advancing medical science. Secretome Therapeutics has achieved significant milestones in preclinical research, positioning itself as a promising player in the biotech industry. Their impact is marked by the potential to revolutionize treatment paradigms for inflammatory and mitochondrial diseases, offering hope for improved quality of life for affected patients.
Companies similar to Secretome Therapeutics include Noveome Biotherapeutics, Cell Care Therapeutics, Stealth BioTherapeutics and NeoProgen.
Secretome Therapeutics was founded in 2018.
Secretome Therapeutics' headquarters is located in Baltimore, MD, US.
Secretome Therapeutics' most recent funding round was for $6.9M (USD) in February 2023.
As of Feb 2, 2023, Secretome Therapeutics has disclosed funding of $6.9M (USD). Undisclosed round amounts are excluded.
Secretome Therapeutics has 8 employees as of Feb 5, 2024.
NeoProgen
